A new step in cancer immunotherapy: researchers from the University of Oslo/Oslo University Hospital and the Netherlands Cancer Institute show that even if one’s own immune cells cannot recognise and fight their tumours, someone else’s immune cells might.

Their proof-of-principle study is published in the journal Science.

The extremely rapidly developing field of cancer immunotherapy aims to create technologies that help the body’s own immune system to fight cancer.

There are a number of possible causes that can prevent the immune system from controlling cancer cells.

First, the activity of immune cells is controlled by many ‘brakes’ that can interfere with their function, and therapies that inactivate these brakes are now being tested in many human cancers.

As a second reason, in some patients the immune system may not recognise aberrances in the cancer cells.

As such, helping the immune system to better recognise cancer cells is one of the main focuses in cancer immunotherapy.

Ton Schumacher of the Netherlands Cancer Institute and Johanna Olweus of the University of Oslo/Oslo University Hospital decided to test whether a ‘borrowed immune system’ could ‘see‘ the cancer cells of patients as aberrant.

The recognition of aberrant cells is carried out by immune cells called T cells.

All T cells in our body scan the surface of other cells, including cancer cells, to check whether they display any protein fragments on their surface that should not be there.

Upon recognition of such foreign protein fragments, T cells kill the aberrant cells.

As cancer cells harbour faulty proteins, they can also display foreign protein fragments – also known as neo-antigens - on their surface, much in the way virus-infected cells express fragments of viral proteins.

To address whether the T cells of a patient react to the foreign protein fragments on cancer cells, the research teams first mapped all possible neo-antigens on the surface of melanoma cells from three different patients.

In all 3 patients, the cancer cells seemed to display a large number of different neo-antigens.

But when the researchers tried to match these to the T cells derived from within the patient’s tumours, most of these aberrant protein fragments on the tumour cells went unnoticed.

Next, they tested whether the same neo-antigens could be seen by T-cells derived from healthy volunteers.

Strikingly, these donor-derived T cells could detect a significant number of neo-antigens that had not been seen by the patients’ T cells.

“In a way, our findings show that the immune response in cancer patients can be strengthened; there is more on the cancer cells that makes them foreign that we can exploit. One way we consider doing this is finding the right donor T cells to match these neo-antigens.”, says Ton Schumacher. “The receptor that is used by these donor T-cells can then be used to genetically modify the patient’s own T cells, so these will be able to detect the cancer cells”.

“Our study shows that the principle of outsourcing cancer immunity to a donor is sound.” Says Johanna Olweus “However, more work needs to be done before patients can benefit from this discovery. We are currently exploring high-throughput methods to identify the neo-antigens that T cells can ‘see’ on cancer cells and to isolate the responding cells. But the results showing that we can create cancer-specific immunity from the blood of healthy individuals are already very promising for the development of new precision immunotherapeutic strategies.”

Source: Science